⌕
Inhibrx Biosciences · INBX · Nasdaq
Tenet 45 · Mixed
Compare
$74.18−4.48%At closeTenet 45 · Mixed
$74.18−3.48 (−4.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Inhibrx Biosciences (INBX) Institutional Ownership

13F filers reported holding 11.8% of Inhibrx Biosciences (INBX) shares as of Sep 30, 2026, across 50 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
11.8%
Sep 30, 2026
13F filers
50
quarter ended Sep 30, 2026
13F value
$174.4M
1.7M shares
Quarter's fund flow
Mild accumulation
13 new · 9 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (13 new · 20 increased · 10 reduced · 9 closed). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 50 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 14, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy2,470$84.07↗
Oct 14, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy2,470$85.00↗
Oct 14, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy100$85.76↗
Oct 14, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy2,449$84.07↗
Oct 14, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy2,451$85.00↗
Oct 14, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy100$85.76↗
Sep 28, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy1,500$98.88↗
Sep 28, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy3,000$101.70↗
Sep 25, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy3,324$98.87↗
Sep 25, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy2,176$99.60↗
Sep 23, 2026Kayyem Jon FaizdirectorAcquired · Open-market buy5,000$100.00↗
Sep 16, 2026Kayyem Jon FaizdirectorAcquired · Open-market buy5,000$100.00↗
Sep 15, 2026MANHARD KIMBERLYdirectorDisposed · Open-market sale500$105.05↗
Sep 14, 2026MANHARD KIMBERLYdirectorDisposed · Open-market sale500$110.26↗
Sep 11, 2026MANHARD KIMBERLYdirectorDisposed · Open-market sale500$111.78↗
Sep 9, 2026MANHARD KIMBERLYdirectorDisposed · Open-market sale500$115.80↗
Sep 8, 2026MANHARD KIMBERLYdirectorDisposed · Open-market sale500$115.14↗
Sep 8, 2026Kayyem Jon FaizdirectorAcquired · Open-market buy5,000$113.52↗
Sep 8, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy5,895$99.29↗
Sep 8, 2026Lappe MarkChief Executive OfficerAcquired · Open-market buy6,605$100.64↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Inhibrx Biosciences do institutions hold?

13F filers reported holding 11.8% of Inhibrx Biosciences' shares as of Sep 30, 2026, across 50 filers.

How many 13F filers hold Inhibrx Biosciences?

Inhibrx Biosciences was held by 50 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.